Novo Nordisk A/S Sponsored ADR (NVO)
US FDA says two more doses of Novo Nordisk's weight-loss drug now available
Two more doses of Novo Nordisk's weight-loss drug, Wegovy, is now available, the U.S. Food and Drug Administration's updated shortages list showed on Tuesday.
Fake weight loss drugs spark warnings on Ozempic supply squeeze
Pharmacists have warned against buying fake weight loss jabs online as shortages of Ozempic persist in the UK. The National Pharmacy Association (NPA) said patients were risking their health over a possible “explosion in the unlicensed sale of medication online” on Monday.
3 Unstoppable Stocks to Buy in August
Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.
What You Need To Know Ahead of Novo Nordisk Earnings Wednesday
Novo Nordisk (NVO) is set to report earnings for the second quarter on Wednesday morning after a first half in which the company's market of potential customers for its Ozempic and Wegovy weight-loss drugs expanded.
Novo Nordisk to launch weight-loss drug Wegovy in Australia this month
Danish drugmaker Novo Nordisk will launch its hugely popular weight-loss drug Wegovy in Australia this month, a spokesperson for the company said on Thursday.
Oxford Nanopore soars as Novo Nordisk builds stake
Oxford Nanopore Technologies PLC (LSE:ONT), the London-listed tech group, has rallied close to 12% this morning after it was revealed drug giant Novo Nordisk (NYSE:NVO) had bought a £50 million stake. a UK-listed company specialising in molecular sensing technology based on nanopores.
Focus: Patients push back against Novo Nordisk move to scrap an insulin product
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. states told Reuters.
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Could Send Ozempic's Sales Potential to a Whole Other Level
Ozempic's potential usefulness continues to grow as more studies are done on the diabetes drug. There are multiple potential brain benefits related to using the drug, which could unlock more growth opportunities.
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
There are dozens of investigational GLP-1 medicines in development. Novo Nordisk, the leader in the field, arguably has the most promising candidates.
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
